miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood.
microRNAs (miRNAs) are aberrantly expressed in the whole blood of patients suffering from different types of cancer. Collection of whole blood samples is a minimally invasive procedure. To date, little is known concerning the altered miRNA expression in patients suffering from oral squamous cell carcinoma (OSCC). The present study aimed to evaluate the difference in miRNA expression in whole blood samples in OSCC patients as compared to healthy volunteers who served as controls. In 20 blood samples from patients and healthy volunteers, the expression patterns of 1,205 human miRNAs were examined by miRNA microarray in order to identify those with the most pronounced differential expression. The results were verified by quantitative RT-PCR (RT-qPCR) for miR-186, miR-3651 and miR-494 using 57 samples of patients and 33 samples of healthy volunteers. Receiver operating characteristic (ROC) curves and the highest Youden index were calculated in order to assess cut-off points (COPs) that allowed the distinguishing of blood samples of OSCC patients from those of healthy volunteers. Significantly different expression rates were found for miR-186 (p=0.01), miR-3651 (p=0.0001) and miR-494 (p=0.004) between the OSCC patients and healthy controls. In the OSCC patients, there was a 2-fold upregulation for miR-494 and miR-3651 and a 2-fold downregulation for miR-186. Based on the determined COPs, significant correlations between miR-3651 overexpression and lymph node status (p=0.04), tumor grade (p=0.02) and clinical stage (p=0.04) were indicated. Aberrant expression levels of miR-186, miR-494 and miR-3651 in whole blood samples of OSCC patients may provide the possibility to establish a minimally invasive screening method for OSCC.
Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Erlangen, Germany.
Jutta
J
Ries
Department of Oral and Maxillofacial Surgery, University of Athens, Athens, Greece.
Eleftherios
E
Vairaktaris
Institute of Pathology, Erlangen University Hospital, Erlangen, Germany.
Abbas
A
Agaimy
Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Erlangen, Germany.
Rita
R
Kintopp
Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Erlangen, Germany.
Christoph
C
Baran
Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Erlangen, Germany.
Friedrich W
FW
Neukam
Department of Oral and Maxillofacial Surgery, Erlangen University Hospital, Erlangen, Germany.
Emeka
E
Nkenke
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D015870:Gene Expression; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D008840:Microfilament Proteins; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000097:blood*; D016601:RNA-Binding Proteins; D012372:ROC Curve
D014408:Biomarkers, Tumor; C484440:Frg1 protein, mouse; C533096:MIRN186 microRNA, human; C547168:MIRN494 microRNA, human; D035683:MicroRNAs; D008840:Microfilament Proteins; D016601:RNA-Binding Proteins